Participation of p53 Protein in the Cellular Response to DNA Damage

Cancer Research

Volumn 51, Issue , 1991, Pages 6304-6311

  Kastan, Michael B ^a,b   Onyekwere, Onyinye ^a   Sidransky, David ^a   Vogelstein, Bert ^a   Craig, Ruth W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CYTARABINE; DACTINOMYCIN; PROTEIN P53;

ARTICLE; CARCINOGENESIS; DNA DAMAGE; FLOW CYTOMETRY; GAMMA RADIATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL;

BONE MARROW CELLS; CAFFEINE; CELL CYCLE; CYCLOHEXIMIDE; DACTINOMYCIN; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA, NEOPLASM; EXONS; FLOW CYTOMETRY; GENES, P53; HUMAN; MUTATION; PROTEIN P53; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0026318356     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Doll, R., and Peto, R. The causes of cancer in the United States today. J. Nati. Cancer Inst., 66: 1192-1308, 1981.
2. Tolmach, L. J., Jones, R. W., and Busse, P. M. The action of caffeine on Xirradiated HeLa cells. I. Delayed inhibition of DNA synthesis. Radiant.Res., 71: 653-665, 1977.
3. Smerdon, M. J., Kastan. M. B., and Lieberman. M. W. Distribution of repair-incorporated nucleotides and nucleosome rearrangement in the chromatin of normal and xeroderma pigmentosum human fibroblasts. Biochem istry. 18: 3732-3739, 1979.
4. Painter, R. B., and Young, B. R. Radiosensitivity in ataxia-telangiectasia: a new explanation. Proc. Nati. Acad. Sci. USA, 77: 7315-7317, 1980.
5. Denekamp, J. Cell kinetics and radiation biology. Int. J. Radiat,limi, 49: 357-380, 1986.
6. Weinert, T. A., and Hartwell, L. H. The RAD9 gene controls the cell cycle response to DNA damage in saccharomyces cerevisiae. Science (Washington DC), 241: 317-322, 1988.
7. Cohen, S. M., and Ellwein, L. B. Cell proliferation in carcinogenesis. Science (Washington DC). 249: 1007-1011, 1990.
8. Bremner, R., and Balmain, A. Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell, 61: 407-417, 1990.
9. Fearon, E. R., and Vogelstein, B. A genetic model for colorectal tumorigen esis. Cell, 61: 759-767, 1990.
10. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., and Vogelstein. B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Washington DC). 249: 912-915, 1990.
11. Diller, L., Kassel Nelson, C. E., Gryka, M. A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M., Baker, S. J., Vogelstein, B., and Friend, S. H. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol., 10: 5772-5781, 1990.
12. Mercer, W. E., Shields, M. T., Amin, M., Sauve, G. J., Appella. E., Romano. J. W., and Ullrich, S. J. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc. Nati. Acad. Sci. USA, 87:6166-6170, 1990.
13. Martinez, J., Georgoff, I., Martinez, J., and Levine, A. J. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev., 5: 151-159, 1991.
14. Vogelstein, B. A deadly inheritance. Nature (Lond.), 348: 681-682, 1990.
15. Hollstein, M., Sidransky, D., Vogelstein. B., and Harris. C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
16. Oren, M., Maltzman, W., and Levine, A. J. Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol. Cell. Biol., 1: 101-110, 1981.
17. Reich, N. C., Oren, M., and Levine, A. J. Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol. Cell. Biol., 3: 2143-2150, 1983.
18. Rogel, A., Popliker, M., Webb, C. G., and Oren, M. p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol. Cell. Biol., 5: 2851-2855, 1985.
19. Finlay, C. A., Hinds, P. W., Tan, T-H., Eliyahu. D., Oren. M., and Levine, A. J. Activating mutations for transformation by p53 produce a gene product that forms an hsclO-p53 complex with an altered half-life. Mol. Cell. Biol., 5: 531-539, 1988.
20. Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., and Oren, M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Nati. Acad. Sci. USA, 86: 8763-8767, 1989.
21. Finlay, C. A., Hinds, P. W., and Levine, A. J. The p53 proto-oncogene can act asa suppressor of transformation. Cell, 57: 1083-1093, 1989.
22. Kastan, M. B., Radin, A. I., Kuerbitz. S. J., Onyekwere, O., Wolkow, C. A., Civin, C. I., Stone, K. D., Woo, T., Ravindranath, Y., and Craig, R. W. Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res., 51:4279-4286, 1991.
23. Maltzman, W., and Czyzyk, L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol., 4: 1689-1694, 1984.
24. Kastan, M. B., Slamon, D. J., and Civin, C. I. Expression of proto-oncogene c-myb in normal human hematopoietic cells. Blood, 73: 1444-1451, 1989.
25. Wade-Evans, A., and Jenkins, J. R. Precise epitope mapping of the murine transformation-association protein, p53. EMBO J., 4: 699-706, 1985.
26. Kastan, M. B., Stone, K. D., and Civin, C. I. Nuclear oncoprotein expression as a function of lineage, differentiation stage, and proliferative status of normal human hematopoietic cells. Blood, 74: 1517-1524, 1989.
27. Berger, S. L., and Chirgwin, J. M. Isolation of RNA. Methods Enzymol., 180: 3-13, 1989.
28. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Labo ratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
29. Feinberg, A. P., and Vogelstein, B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Ann. Biochem., 132:6-\3, 1983.
30. Klempnauer, K-H., and Sippel. A. E. Subnuclear localization of proteins encoded by the oncogene v-myb and its cellular homolog c-myb. Mol. Cell. Biol., 6: 62-69, 1986.
31. Hoy, C. A., Seamer, L. C., and Schimke, R. T. Thermal denaturation of DNA for immunochemical staining of incorporated bromodeoxyuridine (BrdUrd): critical factors that affect the amount of fluorescence and the shape of BrdUrd/DNA histograms. Cytometry. 10: 718-725, 1989.
32. Sidransky, D., Von Eschenbach, A., Tsai, Y. C., Jones, P., Summerhayes, I., Marshall, F., Paul, M., Green, P., Hamilton. S. R., Frost, P., and Vogelstein, B. Identification of p53 gene mutations in bladder cancers and urine samples. Science (Washington DC), 252: 706-709, 1991.
33. Trask, D. K., and Muller M. T. Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc. Nati. Acad. Sci. USA. 85:1417-1421, 1988.
34. Wasserman, K., Markovits, J., Jaxel, C., Capranico, G., Kohn, K. W., and Pommier, Y. Effects of morpholinyl doxorubicins, doxorubicin, and actino mycin D on mammalian topoisomerases I and II. Mol. Pharmacol., 38: 38-45, 1990.
35. Rashbaum, S. A., and Cozzarelli, N. R. Mechanism of DNA synthesis inhibition by arabinosyl cytosine and arabinosyl adenine. Nature (Lond.), 264:679, 1976.
36. Craig. R. W., Frankfurt, O. S., Sakagami, H., Takeda, K., and Bloch, A. Macromolecular and cell cycle effects of different classes of agents inducing the maturation of human myeloblastic leukemia (ML-1) cells. Cancer Res., 44:2421-2429. 1984.
37. Walters, R., Gurley, L. R., and Tobey, R. A. Effects of caffeine on radiationinduced phenomena associated with cell-cycle traverse of mammalian cells. Biophys. J., 14: 99-118. 1974.
38. Lau, C. C., and Pardee, A. B. Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc. Nati. Acad. Sci. USA, 79: 2942-2946, 1982.
39. Weinert, T. A., and Hartwell, L. H. Characterization of RAD9 of saccharo myces cerevisiae and evidence that its function acts posttranslationally in cell cycle arrest after DNA damage. Mol. Cell. Biol., 10:6554-6564, 1990.
40. Wolf, D., and Rotter, V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc. Nati. Acad. Sci. USA, 82: 790-794, 1985.
41. Marshall, C. J. Tumor suppressor genes. Cell, 64: 313-326. 1991.
42. Lane. D. P., and Crawford, L. V. T antigen is bound to a host protein in SV40-transformed cells. Nature (Lond.), 278: 261-263, 1979.
43. Kraiss, S., Quaiser, A., Oren. M., and Montenarh, M. Oligomerization of oncoprotein p53. J. Virol., 62: 4737-4744, 1988.
44. Bischoff, J. R., Friedman, P. N., Marshak, D. R., Prives, C., and Beach, D. Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc. Nati. Acad. Sci. USA, 87: 4766-4770, 1990.
45. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63: 1129-1136, 1990.
46. Milner, J., Cook, A., and Mason, J. p53 is associated with p34cd(:2in transformed cells. EMBO J., 9: 2885-2889, 1990.
47. Lock, R. B., and Ross, W. E. Inhibition of p34cdc2kinase activity by etoposide or irradiation as a mechanism of Gaarrest in Chinese hamster ovary cells. Cancer Res., 50: 3761-3766. 1990.
48. Yunis. J. J. Genes and chromosomes in human cancer. Adv. Oncol., 6: 3-7, 1990.
49. Malkin, D., Li. F. P., Strong, L. C., Fraumeni, J. F., Jr., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., and Friend, S. H. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (Washington DC), 250: 1233-1238, 1990.
50. Srivasta, S., Zou, Z., Pirollo, K., Blattner, W., and Chang, E. H. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li- Fraumeni syndrome. Nature (Lond.), 348: 747-749, 1990.
51. Bischoff, F. Z., Yim, S. O., Pathak, S., Grant, G., Siciliano, M. J., Giovanella. B. C., Strong, L. C., and Tainsky, M. A. Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization. Cancer Res., 50: 7979-7984, 1990.
52. Li. F. P., and Fraumeni, J. F., Jr. Prospective study of a family cancer syndrome. J. Am. Med. Assoc., 247: 2692-2694, 1982.
53. Li, F. P., Fraumeni, J. F., Jr., Mulvihill, J. J., Blattner, W. A., Dreyfus, M. G., Tucker, M. A., and Miller, R. W. A cancer family syndrome in 24 kindreds. Cancer Res., 48: 5358-5362, 1988.